Format

Send to

Choose Destination
Lab Invest. 2006 Oct;86(10):981-6. Epub 2006 Aug 21.

Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors.

Author information

1
Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA. bprubin@u.washington.edu

Abstract

A growing number of tumors are characterized by simple genetic changes that activate important biochemical pathways, which are involved in their pathogenesis. These findings have led to the concept of targeted small molecule inhibitor treatment. The prototype for this type of therapy has been treatment of chronic myelogenous leukemia with imatinib mesylate (Gleevec), which targets BCR-ABL kinase. More recently, imatinib has been used to inhibit KIT in gastrointestinal (GI) stromal tumor, a mesenchymal tumor that arises in the GI tract. Furthermore, it has been possible to target EGFR in non-small-cell lung cancer with gefitinib and erlotinib. While initial results have been encouraging, resistance to small molecule kinase inhibitors is a substantial drawback. This paper focuses on what is known about mechanisms of resistance in the treatment of solid tumors by small molecule kinase inhibitors.

PMID:
16924245
DOI:
10.1038/labinvest.3700466
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center